AR075908A1 - Formulacion farmaceutica que contiene moleculas de anticuerpo mejoradas, polipeptidos. metodo para estabilizar solucion, anticuerpo. - Google Patents
Formulacion farmaceutica que contiene moleculas de anticuerpo mejoradas, polipeptidos. metodo para estabilizar solucion, anticuerpo.Info
- Publication number
- AR075908A1 AR075908A1 ARP100100904A ARP100100904A AR075908A1 AR 075908 A1 AR075908 A1 AR 075908A1 AR P100100904 A ARP100100904 A AR P100100904A AR P100100904 A ARP100100904 A AR P100100904A AR 075908 A1 AR075908 A1 AR 075908A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- sequence
- cdr1
- cdr2
- cdr3
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicacion 1: Una formulacion farmacéutica, caracterizada porque comprende al menos un polipéptido seleccionado entre: (a) un polipéptido que comprende una CDR1 que comprende la secuencia de la SEQ ID N°:1 (CDR1 de VH4-M73), una CDR2 que comprende la secuencia de la SEQ ID N°:2 (CDR2 de VH4-M73) y una CDR3 que comprende la secuencia de la SEQ ID N°:3 (CDR3 de VH4-M73); (b) un polipéptido que comprende una CDR1 que comprende la secuencia de la SEQ ID N°:4 (CDR1 de VH3-M73), una CDR2 que comprende la secuencia de la SEQ ID N°:5 (CDR2 de VH3-M73) y una CDR3 que comprende la secuencia de la SEQ ID N°:6 (CDR3 de VH3-M73); (c) un polipéptido que comprende una CDR1 que comprende la secuencia de la SEQ ID N°:7 (CDR1 de VH5-M83), una CDR2 que comprende la secuencia de la SEQ ID N°:8 (CDR2 de VH5-M83) y una CDR3 que comprende la secuencia de la SEQ ID N°:9 (CDR3 de VH5-M83); (d) un polipéptido que comprende una CDR1 que comprende la secuencia de la SEQ ID N°:10 (CDR1 de VL1), una CDR2 que comprende la secuencia de la SEQ ID N°:11 (CDR2 de VL1) y una CDR3 que comprende la secuencia de la SEQ ID N°:12 (CDR3 de VL1); e) un polipéptido que comprende una CDR1 que comprende la secuencia de la SEQ ID N°:13 (CDR1 de VL3), una CDR2 que comprende la secuencia de la SEQ ID N°:14 (CDR2 de VL3) y una CDR3 que comprende la secuencia de la SEQ ID N°:15 (CDR3 de VL3); y (f) un polipéptido que comprende una CDR1 que comprende la secuencia de la SEQ ID N°:16 (CDR1 de VL5), una CDR2 que comprende la secuencia de la SEQ ID N°:17 (CDR2 de VL5) y una CDR3 que comprende la secuencia de la SEQ ID N°:18 (CDR3 de VL5). Reivindicacion 5: Una formulacion farmacéutica estable de acuerdo con cualquiera de las reivindicaciones 1 a 4, caracterizada porque comprende 1-500 mM de agente amortiguador de histidina y/o citrato, 1-1500 mM de al menos un aminoácido cationico, 1-200 mg/mL de anticuerpo, y 1-400 mM de un carbohidrato. Reivindicacion 12: La formulacion de acuerdo con cualquiera de las reivindicaciones 1 a 11, caracterizada porque contiene el polipéptido y/o anticuerpo en una cantidad inferior o igual a 240 mg/ml. Reivindicacion 15: La formulacion de acuerdo con cualquiera de las reivindicaciones 1 a 14, caracterizada porque la formulacion es líquida. Reivindicacion 16: La formulacion de acuerdo con la reivindicacion 15, caracterizada porque no se sometio a liofilizacion durante la preparacion de la misma.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009069095 | 2009-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075908A1 true AR075908A1 (es) | 2011-05-04 |
Family
ID=42739479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100904A AR075908A1 (es) | 2009-03-19 | 2010-03-19 | Formulacion farmaceutica que contiene moleculas de anticuerpo mejoradas, polipeptidos. metodo para estabilizar solucion, anticuerpo. |
Country Status (8)
| Country | Link |
|---|---|
| JP (2) | JP4885308B2 (es) |
| KR (1) | KR101468271B1 (es) |
| AR (1) | AR075908A1 (es) |
| AU (1) | AU2010225951B2 (es) |
| RU (1) | RU2565809C2 (es) |
| SG (3) | SG10201900451SA (es) |
| TW (1) | TWI440470B (es) |
| WO (1) | WO2010106812A1 (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101479381B (zh) | 2006-03-31 | 2015-04-29 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| CN106519025B (zh) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| AR080428A1 (es) | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
| SG183867A1 (en) | 2010-03-11 | 2012-10-30 | Rinat Neuroscience Corp | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
| KR20220070586A (ko) | 2010-11-08 | 2022-05-31 | 제넨테크, 인크. | 피하 투여용 항―ｉｌ―6 수용체 항체 |
| JP6030452B2 (ja) | 2010-11-30 | 2016-11-24 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
| US20140080153A1 (en) * | 2011-01-07 | 2014-03-20 | Chugai Seiyaku Kabushiki Kaisha | Method for improving physical properties of antibody |
| WO2012132067A1 (ja) * | 2011-03-30 | 2012-10-04 | 中外製薬株式会社 | 抗原結合分子の血漿中滞留性と免疫原性を改変する方法 |
| SG192945A1 (en) | 2011-02-25 | 2013-09-30 | Chugai Pharmaceutical Co Ltd | Fcgriib-specific fc antibody |
| UY34105A (es) | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
| US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
| CA3233142A1 (en) | 2011-11-30 | 2013-06-06 | Chugai Seiyaku Kabushiki Kaisha | Drug containing carrier into cell for forming immune complex |
| WO2014163101A1 (ja) | 2013-04-02 | 2014-10-09 | 中外製薬株式会社 | Ｆｃ領域改変体 |
| WO2015095712A1 (en) * | 2013-12-20 | 2015-06-25 | Diogenix, Inc. | Methods for evaluating neurological disease |
| MY181081A (en) * | 2013-12-27 | 2020-12-17 | Chugai Pharmaceutical Co Ltd | Method for purifying antibody having low isoelectric point |
| TWI805046B (zh) | 2015-02-27 | 2023-06-11 | 日商中外製藥股份有限公司 | Il-6受體抗體用於製備醫藥組成物的用途 |
| WO2016190263A1 (ja) | 2015-05-22 | 2016-12-01 | アステラス製薬株式会社 | 新規抗ヒトＮＧＦ抗体Ｆａｂフラグメント |
| TWI836745B (zh) | 2015-12-18 | 2024-03-21 | 美商上游生物公司 | 含有抗人類ｔｓｌｐ受體抗體之醫藥組成物 |
| JP2019534863A (ja) * | 2016-09-27 | 2019-12-05 | フレゼニウス カービ ドイチュラント ゲーエムベーハー | 液体医薬組成物 |
| US20200283516A1 (en) * | 2017-03-01 | 2020-09-10 | Medimmune Limited | Formulations of monoclonal antibodies |
| JP7185884B2 (ja) | 2017-05-02 | 2022-12-08 | 国立研究開発法人国立精神・神経医療研究センター | Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法 |
| EP3698808A4 (en) | 2017-10-20 | 2021-07-14 | Hyogo College Of Medicine | MEDICAL COMPOSITION CONTAINING ANTI-IL-6 RECEPTOR ANTIBODIES FOR THE PREVENTION OF POSTOPERATIVE ADHESION |
| US20220071901A1 (en) * | 2017-11-30 | 2022-03-10 | Bio-Thera Solutions, Ltd. | A liquid formulation of humanized antibody for treating il-6-mediated diseases |
| JP7458790B2 (ja) | 2018-01-31 | 2024-04-01 | 元一 加藤 | Ｉｌ－６阻害剤を含有する喘息の治療剤 |
| EP3843852A1 (en) | 2018-08-29 | 2021-07-07 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for treating subjects having rheumatoid arthritis |
| BR112021014377A2 (pt) | 2019-01-31 | 2021-12-28 | Regeneron Pharma | Composições e métodos para o tratamento de artrite idiopática juvenil |
| KR20210144795A (ko) | 2019-03-29 | 2021-11-30 | 추가이 세이야쿠 가부시키가이샤 | 항il-6 수용체 항체를 함유하는 bbb 기능 저하의 억제제 |
| JP7501876B2 (ja) | 2019-04-17 | 2024-06-18 | 国立大学法人広島大学 | Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤 |
| JP7466640B2 (ja) | 2020-05-29 | 2024-04-12 | 中外製薬株式会社 | 抗体含有製剤 |
| KR20220028972A (ko) * | 2020-08-31 | 2022-03-08 | (주)셀트리온 | 안정한 약제학적 제제 |
| IL305793A (en) | 2021-03-12 | 2023-11-01 | Hoffmann La Roche | A pharmaceutical preparation for the treatment or prevention of myasthenia gravis |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL199659B1 (pl) * | 1998-02-25 | 2008-10-31 | Merck Patent Gmbh | Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2 |
| DK1562968T3 (da) * | 2001-11-14 | 2013-10-28 | Janssen Biotech Inc | Anti-il-6-antistoffer, sammensætninger, fremgangsmåder og anvendelser |
| EP2311489A3 (en) * | 2002-02-14 | 2013-08-21 | Chugai Seiyaku Kabushiki Kaisha | Formulation of antibody-containing solutions comprising a sugar as a stabilizer |
| PT1562972E (pt) * | 2002-10-15 | 2010-11-10 | Facet Biotech Corp | Alteração de afinidades de ligação ao fcrn ou semi-vidas séricas de anticorpos por mutagénese |
| KR101235507B1 (ko) * | 2003-02-28 | 2013-02-20 | 추가이 세이야쿠 가부시키가이샤 | 단백질을 함유하는 안정화 제제 |
| JP4685764B2 (ja) * | 2003-04-10 | 2011-05-18 | アボット バイオセラピューティクス コーポレイション | 変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変 |
| WO2005080429A2 (en) * | 2004-02-11 | 2005-09-01 | Warner-Lambert Company Llc | Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| JP5231810B2 (ja) * | 2005-12-28 | 2013-07-10 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| EP1988922A4 (en) * | 2006-02-03 | 2010-06-02 | Medimmune Llc | PROTEIN FORMULATIONS |
| CN101479381B (zh) * | 2006-03-31 | 2015-04-29 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| RS52643B (en) * | 2006-06-02 | 2013-06-28 | Regeneron Pharmaceuticals Inc. | HIGH AFINITY ANTIBODIES TO THE HUMAN IL-6 RECEPTOR |
| CN106519025B (zh) * | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| CN101939425B (zh) * | 2007-09-26 | 2014-05-14 | 中外制药株式会社 | 抗il-6受体抗体 |
| KR101922788B1 (ko) * | 2007-09-26 | 2018-11-27 | 추가이 세이야쿠 가부시키가이샤 | 항체 정상영역 개변체 |
| KR102057826B1 (ko) * | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
-
2010
- 2010-03-19 AR ARP100100904A patent/AR075908A1/es unknown
- 2010-03-19 SG SG10201900451SA patent/SG10201900451SA/en unknown
- 2010-03-19 AU AU2010225951A patent/AU2010225951B2/en active Active
- 2010-03-19 JP JP2010522524A patent/JP4885308B2/ja active Active
- 2010-03-19 SG SG10201703707YA patent/SG10201703707YA/en unknown
- 2010-03-19 KR KR1020117024548A patent/KR101468271B1/ko active IP Right Grant
- 2010-03-19 SG SG2011066768A patent/SG174428A1/en unknown
- 2010-03-19 WO PCT/JP2010/001977 patent/WO2010106812A1/en active Application Filing
- 2010-03-19 TW TW099108118A patent/TWI440470B/zh active
- 2010-03-19 RU RU2011142184/10A patent/RU2565809C2/ru active
-
2011
- 2011-05-09 JP JP2011104179A patent/JP5661553B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| RU2011142184A (ru) | 2013-04-27 |
| SG10201900451SA (en) | 2019-02-27 |
| TWI440470B (zh) | 2014-06-11 |
| JP4885308B2 (ja) | 2012-02-29 |
| SG10201703707YA (en) | 2017-06-29 |
| AU2010225951B2 (en) | 2014-03-13 |
| KR20110139745A (ko) | 2011-12-29 |
| SG174428A1 (en) | 2011-10-28 |
| TW201100100A (en) | 2011-01-01 |
| JP2012504106A (ja) | 2012-02-16 |
| WO2010106812A1 (en) | 2010-09-23 |
| JP5661553B2 (ja) | 2015-01-28 |
| JP2011173918A (ja) | 2011-09-08 |
| RU2565809C2 (ru) | 2015-10-20 |
| AU2010225951A1 (en) | 2011-09-22 |
| KR101468271B1 (ko) | 2014-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075908A1 (es) | Formulacion farmaceutica que contiene moleculas de anticuerpo mejoradas, polipeptidos. metodo para estabilizar solucion, anticuerpo. | |
| EP4233892A3 (en) | Stable anti-ifnar1 formulation | |
| EA200970880A1 (ru) | Стабильные композиции на основе антител | |
| PH12017500844A1 (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
| NZ719036A (en) | Anti-pdl1 antibody formulations | |
| Teng et al. | An animal model of glomerular light-chain-associated amyloidogenesis depicts the crucial role of lysosomes | |
| AR076748A1 (es) | Formulaciones estables de anticuerpos anti-tnf-alfa humanos con grandes concentraciones de proteinas. metodo de tratamiento | |
| PE20141727A1 (es) | Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas | |
| MX363700B (es) | Formulaciones farmaceuticas de anticuerpos tnf-alfa. | |
| BR112012022223A2 (pt) | formulações de proteína concentrada e usos das mesmas | |
| RU2013137740A (ru) | Жидкая композиция, содержащая антитело высокой концентрации | |
| EA201992570A1 (ru) | Составы на основе человеческих антител к rankl, а также способы их применения | |
| MX2014001372A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico. | |
| ECSP099403A (es) | Formulacion parenteral del anticuerpo abeta | |
| AR095451A1 (es) | Formulación de anticuerpos | |
| MX361668B (es) | Formulación de anticuerpos. | |
| BRPI0606867A2 (pt) | formulação lìquida; forma de dosagem unitária farmacêutica; kit; recipiente; método para aumentar a estabilidade de um polipeptìdeo de ligação a antìgeno numa formulação; método para preparar uma forma de dosagem unitária farmacêutica; formulação estável; formulação; e produto terapêutico | |
| EA201391756A1 (ru) | Композиции, содержащие, способы, включающие, и применение производных доластатина, связанных с неприродными аминокислотами | |
| ES2564281T3 (es) | Formulación de anticuerpos Abeta | |
| AR082257A1 (es) | Composicion de inmunoglobulinas humanas concentradas, procedimiento | |
| PE20120170A1 (es) | Variantes de union a anti-albumina de suero mejoradas | |
| PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
| PE20190733A1 (es) | Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y metodos de uso | |
| BR112016014913A8 (pt) | anticorpo, ou um fragmento de ligação ao antígeno do mesmo, conjugado, ácido nucléico, vetor, célula hospedeira, composição farmacêutica, método de preparo de uma cadeia leve de um anticorpo ou fragmento de ligação ao antígeno e método de preparo de um conjugado | |
| NZ702342A (en) | Pharmaceutical formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |